Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7141 to 7155 of 8218 results

  1. Conjunctivitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10166

    Antimicrobial prescribing guideline
    Discontinued

  2. Blepharitis: antimicrobial prescribing

    Discontinued Reference number: GID-NG10168

    Antimicrobial prescribing guideline
    Discontinued

  3. Stye: antimicrobial prescribing

    Discontinued Reference number: GID-NG10167

    Antimicrobial prescribing guideline
    Discontinued

  4. Skin abscess: antimicrobial prescribing

    Discontinued Reference number: GID-NG10163

    Antimicrobial prescribing guideline
    Discontinued

  5. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

    NICE guideline
    Discontinued

  6. Oral semaglutide for managing overweight and obesity [ID6188]

    Discontinued Reference number: GID-TA11149

    Technology appraisal guidance
    Discontinued

  7. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development Reference number: GID-TA11189 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861]

    In development Reference number: GID-TA11345 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Peezy Midstream for urine collection (MT446)

    In development Reference number: GID-MT538 Expected publication date: TBC

    Medical technologies guidance
    In development

  10. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene for babies 6 months and over to children under 2 years TS ID 11774

    Discontinued Reference number: GID-TA11124

    Technology appraisal guidance
    Discontinued

  11. Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]

    In development Reference number: GID-TA11455 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development Reference number: GID-TA11523 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued Reference number: GID-MT557

    Medical technologies guidance
    Discontinued

  14. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued Reference number: GID-MT563

    Medical technologies guidance
    Discontinued

  15. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued Reference number: GID-MT517

    Medical technologies guidance
    Discontinued